glp-1 cirrhosis Why are agonists being used to treat patients with nonalcoholic fatty liver disease? Exploring the Potential of GLP-1

Some obesity medicine specialists suggest higher intakes for specific populations, particularly patients who are physically active, older adults at higher risk for sarcopenia, or those losing weight rapidly

Update on the Effects of GLP-1 Receptor Agonists for the Treatment of Polycystic Ovary Syndrome

None of this is a prescription from us, it is context so you can evaluate claims for yourself

We excluded participants who left at least 1 TTO or VAS question blank or incomplete (noncompleters) and respondents who reported the same answer for all TTO scenarios (nontraders)

Nein GLP-1 ist kein Insulin

After propensity-score matching, the two cohorts (26,784 in each cohort, mean age 51.3 years, 65.6% women, 16.1% Black, 66.5% White, 6.7% Hispanic) were balanced (Table 1)